Novavax | NVAX - Gross Profit On Sales

Stock Price
8.45
Daily Change
-0.50 -5.59%
Monthly
-16.42%
Yearly
20.71%
Q1 Forecast
8.20

Novavax reported $125.04M in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
Adma Biologics USD 88.82M 13.19M Dec/2025
Agenus USD 34.2M 4.61M Dec/2025
AstraZeneca USD 12.39B 5M Dec/2025
BioCryst Pharmaceuticals USD 153.05M 4.16M Dec/2025
Cassava Sciences USD -3.96M 1.16M Sep/2025
Geron USD 46.71M 525K Dec/2025
GlaxoSmithKline GBP 6.18B 106M Dec/2025
MannKind USD 78.31M 76.21M Dec/2025
Merck USD 13.42B 431M Sep/2025
Minerva Neurosciences -4.27M 26.79M Dec/2024
Moderna USD 226M 583M Dec/2025
Novartis USD 10.82B 694M Sep/2025
Novavax USD 125.04M 76.09M Dec/2025
Pfizer USD 3.54B 7.61B Sep/2025
Sanofi EUR 8.45B 1.31B Dec/2025
Sarepta Therapeutics USD 43.55M 204.36M Dec/2025
TG Therapeutics USD 154.43M 20.81M Dec/2025